Vascular Medicine News

The gender gap in life expectancy in the United States has grown in recent years, with women living nearly 6 years longer than men on average, according to the results of a study published in JAMA Internal Medicine.

PHILADELPHIA — An intensive systolic BP target of less than 120 mm Hg for Asian patients with hypertension reduced risk for CV and all-cause mortality over 3 years vs. standard care, a speaker reported.

PHILADELPHIA — Two observational studies presented at the American Heart Association Scientific Sessions linked regular marijuana use to elevated risk for HF and elevated risk for major adverse cardiac and cerebrovascular events.

PHILADELPHIA — A novel single-dose CRISPR base-editing infusion for patients with heterozygous familial hypercholesterolemia and advanced CAD reduced serum PCSK9 and lowered LDL by up to 55% in one patient, a speaker reported.

PHILADELPHIA — Zilebesiran, an investigational subcutaneous RNA interference therapeutic, lowered systolic blood pressure at 3 months and sustained the reduction to 6 months, according to results of the phase 2 KARDIA-1 trial.

PHILADELPHIA — In a new trial, remote self-monitoring of blood pressure and physician-guided titration of medication after a hypertensive pregnancy lowered BP during the first 9 months postpartum more than usual care, a speaker reported.

PHILADELPHIA — In a phase 2b trial, abelacimab, a novel factor XI inhibitor, drastically reduced bleeding compared with rivaroxaban in patients with atrial fibrillation requiring stroke prevention.

PHILADELPHIA — Data presented at the American Heart Association Scientific Sessions show that higher overall CV health as measured by the Life’s Essential 8 score is associated with lower biological age.

PHILADELPHIA — A 48-month intervention to lower BP in patients with uncontrolled hypertension also reduced risk for dementia and cognitive impairment, according to data presented at the American Heart Association Scientific Sessions.

PHILADELPHIA — In patients without diabetes or heart failure presenting with acute MI and impaired left ventricular function, dapagliflozin improved cardiometabolic outcomes compared with placebo, according to the DAPA-MI trial.